Overview of Bentylol

Here is a quick overview of the essential facts about the medication Bentylol (Dicycloverine).

Property	Description
Active Ingredient	Dicycloverine (Dicyclomine) hydrochloride
Form	Capsules, Tablets, Oral Syrup, Injectable Solution
Pharmacological Class	Antispasmodic Agent, Anticholinergic Agent
Origin	Synthetic Compound
General Purpose	Relief of smooth muscle spasms and cramping

What Type of Medicine is Bentylol (Dicycloverine)?

Bentylol is the trade name for the prescription-only synthetic medication whose active substance is Dicycloverine, officially recognized as Dicyclomine. It is primarily categorized as an antispasmodic agent and an anticholinergic agent. The anticholinergic classification relates to its antagonistic effect on muscarinic receptors. Dicyclomine targets and relaxes the muscles of the digestive tract, a property used for addressing functional bowel discomfort.

Dicycloverine’s Composition and Available Forms

The medication is a single-ingredient product, with Dicycloverine hydrochloride serving as the sole active component. The drug is supplied in multiple dosage forms to accommodate various patient needs and administration methods, a feature that distinguishes its flexibility in therapeutic use. These forms include solid oral preparations, such as capsules and tablets, a liquid oral syrup used in cases where swallowing tablets is difficult, and an injectable solution intended for intramuscular administration. The compound itself is a synthetic tertiary amine, differentiating it from compounds derived from natural sources.

General Purpose and Mechanism Summary

The general purpose of Bentylol is to decrease the frequency and intensity of painful involuntary contractions and spasms of the smooth muscles in the gastrointestinal tract, such as those that can cause acute abdominal cramping. This means the medication works by directly acting on the muscle to relax it and by blocking the nerve signals that prompt these muscles to contract, thereby calming the digestive system. Its dual mechanism of action is recognized as a strategy against visceral spasm.

Regulatory References

National Library of Medicine confirmed that Dicyclomine primarily targets and relaxes the muscles of the digestive tract

What side effects are possible with Bentylol?

Possible Side Effects and Safety Information

The safety profile for Bentylol (Dicycloverine) is defined by its classification as an anticholinergic agent, with adverse reactions organized by government regulatory bodies based on frequency and system-organ class.

Common and Expected Adverse Reactions

Adverse effects most frequently reported in clinical studies stem from the medicine’s anticholinergic activity, primarily affecting the central nervous system, eyes, and digestive tract. Reactions documented as common include dry mouth, dizziness, blurred vision, nausea, constipation, and drowsiness. These effects relate to System-Organ Classes such as Nervous System Disorders and Gastrointestinal Disorders.

Serious Safety Considerations and Restrictions

Official labeling describes certain adverse events as serious or clinically significant. These include reports of psychosis (e.g., mental confusion, delirium, hallucinations) and the potential for heat prostration due to the suppression of sweating, especially in hot environments.

Regulatory documents impose specific restrictions and contraindications for use. Bentylol is strictly contraindicated in individuals with certain pre-existing conditions, such as angle-closure glaucoma, obstructive diseases of the gastrointestinal or urinary tracts, and myasthenia gravis. Furthermore, the medication is explicitly contraindicated in infants younger than six months due to the reported risk of severe respiratory symptoms.

Overdose and Emergency Response

Overdose of Bentylol (Dicycloverine) results in manifestations consistent with severe anticholinergic toxicity, which are officially documented in regulatory information. Documented clinical presentations often involve profound Central Nervous System (CNS) effects, including excitement, confusion, disorientation, and hallucinations. Physical signs may include mydriasis (dilated pupils), blurred vision, tachycardia (fast heart rate), and hot, dry skin due to decreased sweating, potentially leading to heat prostration.

Severe outcomes documented in official labeling include seizures, coma, and a curare-like action which can result in muscular weakness and paralysis. Due to the potential for severe or life-threatening complications, the official regulatory mandate is to contact a Poison Control Center immediately or seek urgent medical attention for any suspected overdosage.

Regulatory information highlights increased risks in specific patient groups. Infants less than six months of age are particularly vulnerable, with reported events including severe respiratory symptoms and death. Elderly patients are noted to be more susceptible to CNS effects like confusion and excitement. Management described in regulatory documents centers on symptomatic and supportive treatment, including procedural measures like gastric lavage and the use of a parenteral cholinergic agent as an antidote.

Therapeutic Uses of Bentylol

Main Uses of Bentylol

Bentylol is primarily utilized in the management of functional bowel disorders, most notably irritable bowel syndrome (IBS). It belongs to a class of medications known as antispasmodics, which are designed to address specific physical symptoms related to the digestive tract.

Relieving Gastrointestinal Spasms

The primary function of Bentylol is to alleviate smooth muscle spasms in the gastrointestinal tract. In conditions like IBS, the muscles of the intestines may contract irregularly or too forcefully. These spasms are often responsible for significant physical discomfort and disruptions to normal digestive patterns.

Benefits for Abdominal Pain and Discomfort

By helping the intestinal muscles to relax, Bentylol can assist in reducing the intensity of abdominal pain and cramping. When the rhythmic contractions of the digestive system are stabilized, the associated sensation of pressure and bloating may also be diminished.

Management of Bowel Irritability

Bentylol is used to help regulate the hypermotility (excessive movement) of the gut. For patients experiencing bowel irritability, the medication works to slow down these overactive muscle responses, which can help in stabilizing the overall function of the lower digestive tract and improving daily comfort levels.

Eligibility and Restrictions for Use

Bentylol (dicycloverine) eligibility is strictly defined by regulatory authorities based on age, physiological status, and underlying medical conditions.

Populations Who Must Not Use Bentylol

The medicine is contraindicated in the following groups, as stated in the official prescribing information:

Infants less than 6 months of age.
Nursing mothers (Lactation).
Patients with Myasthenia Gravis or glaucoma.
Patients with obstructive diseases of the gastrointestinal tract or urinary tract (obstructive uropathy).
Patients with severe ulcerative colitis or reflux esophagitis.

Eligibility with Caution

Use is only permitted with caution and close monitoring in certain other patient populations:

Geriatric patients (older adults) are more susceptible to the drug's effects.
Patients with known hepatic or renal impairment (liver or kidney disease).
Patients with conditions like Prostatic Hypertrophy or certain cardiac conditions (e.g., coronary heart disease, hypertension).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Bentylol (Dicycloverine) based predominantly on pharmacodynamic effects and altered absorption patterns.

Documented Interaction Patterns

Interaction Type	Interacting Agent Category	Official Interaction Statement
Additive Effects	Other Anticholinergic Agents	Co-administration may increase the likelihood of additive anticholinergic effects.
Antagonism/Risk	Drugs that Alter GI Motility/Antiperistaltic Agents	Dicycloverine may antagonize the effects of pro-motility agents; use with anti-peristaltic drugs may increase the risk of severe complications like toxic megacolon.
Exposure Modification	Antacids	Simultaneous oral administration should be avoided as antacids may interfere with the oral absorption of Dicycloverine.
Exposure Modification	Digoxin (slowly dissolving forms)	Dicycloverine-induced slowing of gastrointestinal motility may increase serum digoxin concentration.
CNS Additive Effects	Alcohol	Alcohol may contribute to increased drowsiness due to additive central nervous system depression.

Official labeling specifies that Dicycloverine’s anticholinergic activity can also antagonize the effects of antiglaucoma agents, potentially leading to an increase in intraocular pressure. Furthermore, geriatric patients may be more susceptible to the additive CNS effects resulting from interactions with other medicines. The use of certain anti-peristaltic agents with Dicycloverine is associated with a specific risk of complications like paralytic ileus, as described in regulatory text.

Mechanism of Action

Dicycloverine acts via a dual mechanism to influence motor activity in the digestive tract by affecting the nervous input and the smooth muscle cell itself.

Antagonizing Cholinergic Nerve Signals

The primary action involves blocking the muscarinic acetylcholine receptors (M1, M2, M3) found across the gastrointestinal (GI) system. Dicycloverine functions as a competitive antagonist, preventing the binding of the neurotransmitter acetylcholine which normally triggers muscle contraction and glandular secretions. This mechanism decreases the cholinergic signaling from the parasympathetic autonomic nervous system, which initiates involuntary muscle contraction (hypermotility).

Direct Spasmolytic Action on Smooth Muscle

Complementing the nerve signal blockade is a secondary, direct myotropic effect on the smooth muscle fibers of the gut wall. This mechanism is independent of receptor blockade; it involves modulating the internal processes, such as the regulation of intracellular calcium (Ca^2+) availability, which is critically required for the muscle fiber to shorten. This dual mechanistic approach results in a reduction in muscle tone and a decrease in the force and frequency of peristaltic contractions, affecting the physiological state of the muscle response.

Dosage and Administration Information

How to Use Bentylol

This section outlines the general principles and patterns for the administration of Bentylol (Dicycloverine).

Administration Routes and Dosing Schedule

Bentylol is administered via two approved routes: Oral (using tablets, capsules, or syrup) and Intramuscular (IM) injection (solution). The standard regimen for both routes requires the dose to be taken four times a day (QID).

Dosing Parameter	Guideline	Contextual Use Principle
Oral Starting Dose	20 mg per administration	Maintained for a one-week trial period.
Maximum Daily Oral Dose	160 mg total	The upper limit guiding total daily oral intake.
IM Dose Range	10 mg to 20 mg per administration	Used only when the oral route is not feasible.

Usage Patterns and Constraints

The treatment protocol establishes duration limits. The initial oral dose regimen is assessed for efficacy, and therapy is generally discontinued if satisfactory response is not achieved after a two-week trial period. The intramuscular administration is reserved for short-term use, with a recommended maximum duration of one or two days.

Special Procedural Conditions: The injectable solution must be administered via the intramuscular route only; use intravenously is restricted. If a scheduled dose is missed, individuals are instructed to continue the normal dosing schedule and should not take an extra dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bentylol

The research on Bentylol (dicycloverine) primarily focuses on its use in managing symptoms associated with functional bowel conditions. The available evidence, sourced from regulatory and scientific literature, helps contextualize how the product was studied and what limitations exist in the current body of knowledge.

Evidence for Use in Irritable Bowel Syndrome (IBS)

The existing research includes Randomized Controlled Trials (RCTs), which form a key part of the evidence for this condition, supplemented by meta-analyses. These studies were evaluated in settings exploring how symptoms change over time and involved comparing the product being evaluated in adult populations diagnosed with IBS against a control group, usually a placebo. Research was conducted during periods of increased symptom activity and focused on outcomes related to physical discomfort.

Studies examined how the product was observed in conditions characterized by fluctuating or episodic manifestations. Research highlights changes measured during the study period, focusing on patient-reported outcomes describing perceived discomfort. Studies monitored the frequency and severity of abdominal pain and episodes of involuntary muscle spasms. Findings describe patterns observed in the studies that involved measurements of overall global symptom scales. The assembled research contributes to the broader evidence landscape but does not determine whether an individual will respond similarly.

The overall body of evidence for this use is characterized as moderate. Findings were mixed across some studies, and the collective evidence is considered heterogeneous. Results apply only to the populations studied under the specific conditions of the trials.

Long-Term Outcomes and Durability of Response

Bentylol was studied for its relevance in trials assessing short-term or episodic symptom patterns, primarily during defined time intervals. Consequently, there is limited information for long-term outcomes, particularly for durability or observation periods beyond the initial study length.

Long-term effects are not fully established because the follow-up durations were typically short in the core efficacy trials. Research provides context but not individual predictions about durability. The available studies provide insight into symptom patterns and short-term changes, but they provide limited insight into outcomes over extended durations, and certainty remains low regarding the long-term patient outcomes beyond the study period.

Consistency, Limitations, and Research Gaps

The research describing the evidence base for Bentylol has certain limitations that affect the certainty of the findings. Evidence quality varies across studies, leading to a degree of heterogeneity in the synthesized evidence.

A key research limitation is that the sample sizes were modest in many of the initial trials used for regulatory review. Furthermore, the follow-up durations were limited, meaning that long-term outcomes are not fully established. These limitations highlight that data are still emerging and that comparative evidence is lacking in several areas of study. Research continues to explore the role of antispasmodic agents in managing functional bowel conditions.

Key Studies & References Dicyclomine Hydrochloride Tablets: Full Prescribing Information

Frequently Asked Questions (FAQ)

Common questions about Bentylol (FAQ)

Q: Is Bentylol considered a muscle relaxer for the stomach?

Bentylol is officially classified as an antispasmodic agent. Its general purpose is described in regulatory documents as decreasing the frequency and intensity of involuntary contractions, or spasms, of the smooth muscles in the gastrointestinal tract.

Q: What is the main difference between Bentylol and other common stomach or gut medicines?

Bentylol is officially described as an antispasmodic and anticholinergic medicine. This means its action is focused on relaxing the digestive tract muscles. This mechanism is distinct from other common gut medicines like antacids, which neutralize stomach acid, or agents that work to reduce acid production.

Q: What is the difference between Bentylol and an antacid?

Bentylol is an antispasmodic medicine that acts on the muscles and nerve signals of the gut. Antacids, in contrast, work to neutralize stomach acid. Official labeling describes that antacids may interfere with the oral absorption of Bentylol.

Q: Is it normal to feel a little dizzy or lightheaded when first starting Bentylol?

Dizziness is officially listed as one of the most common adverse reactions reported in clinical studies of Bentylol. The inclusion of this effect in the official safety profile indicates it is a commonly reported response described in regulatory documents.

Q: Can Bentylol affect sleep patterns or cause insomnia?

Official documents list both somnolence (drowsiness) and insomnia (difficulty falling asleep or staying asleep) as reported nervous system adverse reactions. These effects are associated with the medicine’s anticholinergic activity.

Q: Can Bentylol be taken on an empty stomach? / Do Bentylol's effects change if it's taken with a large meal?

Regulatory-cited information suggests the medicine can be taken with or without food. Official sources also indicate that taking the medicine with food may delay the onset of its effects.

Q: Are there any foods or drinks I should specifically avoid while taking Bentylol?

Official information states that a normal diet may be continued. Beyond the documented interaction with alcohol, the regulatory documents do not specify particular foods for exclusion.

Q: What happens if Bentylol is stopped suddenly?

Official consumer information suggests that in rare cases, if the medicine has been used regularly for a long time or at high doses, stopping suddenly may lead to withdrawal symptoms. These symptoms, as described, may include reports of dizziness, sweating, or vomiting.

Q: Is Bentylol's purpose to heal the gut or just to manage symptoms?

The drug's indicated purpose is for the relief of symptoms associated with functional bowel/irritable bowel syndrome. Its action is focused on managing symptoms, according to the official indication.

Q: What kind of digestive issues is Bentylol not intended to treat?

Bentylol is indicated for managing functional bowel/irritable bowel syndrome symptoms. However, it is strictly contraindicated in patients with various serious conditions described in regulatory documents, including obstructive diseases of the gastrointestinal tract, severe ulcerative colitis, and reflux esophagitis.

Q: How is Bentylol described in regulatory documents regarding pregnancy?

Regulatory documents state that this drug should be used during pregnancy only if clearly needed. Official labeling states that adequate and well-controlled studies of the recommended doses have not been conducted in pregnant women.

Q: Can Bentylol be used by older adults, and are there special considerations?

Official labeling states that Bentylol should be used with caution in older adults. This is because they may be more susceptible to adverse effects like confusion, drowsiness, fast heartbeat, and difficulty urinating.

Q: Are there any warnings about using Bentylol before driving or operating machinery?

Official warnings state that Bentylol may cause drowsiness, dizziness, or blurred vision. Activities requiring mental alertness, such as operating a motor vehicle or machinery, should be avoided until the individual knows how the medicine affects them.

Q: Can Bentylol affect lab test results?

Official information indicates that Bentylol may interfere with certain laboratory tests. This includes tests such as those used to measure gastric secretions, which could potentially cause false results.

Q: What is the recommended approach if someone experiences a less common side effect?

Official consumer information states that any side effects that are severe, persist, or represent unusual problems should be discussed with a healthcare provider, according to regulatory guidelines.

Q: Can Bentylol be taken with pain relievers like Tylenol or Advil?

The official label warns of potential additive effects when Bentylol is taken with other medicines. This warning applies particularly to medicines that have anticholinergic properties or those that cause central nervous system depression.

Q: What if someone accidentally takes more Bentylol than intended?

Symptoms of over-exposure are described in official documents as potentially including enlarged pupils, hot or dry skin, fever, severe dizziness, mental confusion, fast or irregular heartbeat, and difficulty swallowing. In the event of over-exposure, regulatory guidance specifies the need for seeking immediate emergency medical services.

How should Bentylol be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Bentylol — official regulatory information

Labeled storage temperature requirements: Store Bentylol (dicyclomine) capsules and tablets at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Permitted excursions are between 15 C and 30 C (59 F and 86 F).

Light/moisture protection requirements: Protect the medicine from excess heat and moisture. The oral solution and injection must also be protected from freezing.

Handling requirements: The injectable solution should be visually inspected for particulate matter or discoloration before use. All forms must be kept in the container they came in and tightly closed.

Child-protection storage requirements: Bentylol must be kept out of the sight and reach of children. The oral solution is required to be dispensed in a child-resistant closure.

Disposal instructions (as documented in government sources): Any unused or expired product should be disposed of in accordance with local regulatory requirements. Disposal is generally best achieved through a community drug take-back program. If this is unavailable, the drug should be mixed with an undesirable substance (e.g., used coffee grounds, dirt) and placed in a sealed container before being thrown into household trash; it should not be flushed down the toilet.

Bentylol